CLOZAPINE
Manufacturer: Mylan Institutional Inc.
Score: 148.0
Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia and reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. It has a black box warning for severe neutropenia, orthostatic hypotension, bradycardia, syncope, seizures, myocarditis, cardiomyopathy, and increased mortality in elderly patients with dementia-related psychosis. The initial dose is 12.5 mg once or twice daily, with gradual titration to a target dose of 300-450 mg/day. Special considerations are needed for patients with renal or hepatic impairment, CYP2D6 poor metabolizers, pregnancy, nursing mothers, pediatric use, and geriatric use.
Severe neutropenia, orthostatic hypotension, bradycardia, syncope, seizures, myocarditis, cardiomyopathy, and increased mortality in elderly patients with dementia-related psychosis
Dose adjustments may be necessary in patients with concomitant use of CYP1A2, CYP2D6, or CYP3A4 inhibitors or inducers
12.5 mg once or twice daily, with gradual titration to a target dose of 300-450 mg/day